Dive into the latest developments at TCT 2023 as we dissect the low-risk randomized TAVR trials. In this episode, join the conversation with Columbia's Structural Heart and Valve team as they examine updates, share insights, and discuss how the evolving science may reshape our perspectives on TAVR.